Smoking is a risk factor for early conversion to clinically definite multiple sclerosis
- PMID: 18632775
- DOI: 10.1177/1352458508093679
Smoking is a risk factor for early conversion to clinically definite multiple sclerosis
Abstract
Background: Cigarette smoking increases the risk for development of multiple sclerosis and modifies the clinical course of the disease. In this study, we determined whether smoking is a risk factor for early conversion to clinically definite multiple sclerosis after a clinically isolated syndrome.
Methods: We included 129 patients with a clinically isolated syndrome, disseminated white-matter lesions on brain magnetic resonance imaging, and positive oligoclonal bands in the cerebrospinal fluid. The patients' smoking status was obtained at the time of the clinically isolated syndrome.
Results: During a follow-up time of 36 months, 75% of smokers but only 51% of non-smokers developed clinically definite multiple sclerosis, and smokers had a significantly shorter time interval to their first relapse. The hazard ratio for progression to clinically definite multiple sclerosis was 1.8 (95% confidence interval, 1.2-2.8) for smokers compared with non-smokers (P = 0.008).
Conclusions: Smoking is associated with an increased risk for early conversion to clinically definite multiple sclerosis after a clinically isolated syndrome, and our results suggest that smoking is an independent but modifiable risk factor for disease progression of multiple sclerosis. Therefore, it should be considered in the counseling of patients with a clinically isolated syndrome.
Similar articles
-
Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients.Arch Neurol. 2009 Jul;66(7):841-6. doi: 10.1001/archneurol.2009.119. Arch Neurol. 2009. PMID: 19597085
-
Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance.Arch Neurol. 2012 Feb;69(2):183-90. doi: 10.1001/archneurol.2011.1426. Epub 2011 Oct 10. Arch Neurol. 2012. PMID: 21987393 Clinical Trial.
-
The early risk of multiple sclerosis following isolated acute syndromes of the brainstem and spinal cord.Ann Neurol. 1989 Nov;26(5):635-9. doi: 10.1002/ana.410260508. Ann Neurol. 1989. PMID: 2817838
-
Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.Clin Ther. 2009 Jun;31(6):1142-57. doi: 10.1016/j.clinthera.2009.06.007. Clin Ther. 2009. PMID: 19695384 Review.
-
New options for early treatment of multiple sclerosis.J Neurol Sci. 2009 Feb 1;277 Suppl 1:S9-S11. doi: 10.1016/S0022-510X(09)70004-8. J Neurol Sci. 2009. PMID: 19200870 Review.
Cited by
-
Cost-effectiveness of disease-modifying therapies in multiple sclerosis.Curr Neurol Neurosci Rep. 2012 Oct;12(5):592-600. doi: 10.1007/s11910-012-0291-6. Curr Neurol Neurosci Rep. 2012. PMID: 22782520 Review.
-
Lifestyle and Environmental Factors in Multiple Sclerosis.Cold Spring Harb Perspect Med. 2019 Apr 1;9(4):a028944. doi: 10.1101/cshperspect.a028944. Cold Spring Harb Perspect Med. 2019. PMID: 29735578 Free PMC article. Review.
-
Role of Smoking in the Pathogenesis of Multiple Sclerosis: A Review Article.Cureus. 2020 Aug 5;12(8):e9564. doi: 10.7759/cureus.9564. Cureus. 2020. PMID: 32905534 Free PMC article. Review.
-
Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms.Int J Mol Sci. 2012;13(9):11718-11752. doi: 10.3390/ijms130911718. Epub 2012 Sep 18. Int J Mol Sci. 2012. PMID: 23109880 Free PMC article. Review.
-
Multiple sclerosis.Nat Rev Dis Primers. 2018 Nov 8;4(1):43. doi: 10.1038/s41572-018-0041-4. Nat Rev Dis Primers. 2018. PMID: 30410033 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical